Edwards CEO Mussallem details U.S. Sapien sales guidance, updates on CoreValve case | Wall Street Beat
January 8, 2013 by MassDevice staff
Edwards Lifesciences CEO Michael Mussallem updates investors on U.S. sales expectations for its flagship Sapien heart valve and says the end might be near for its long legal battle with Medtronic's CoreValve over transcatheter aortic valve implant patents covering Sapien.
Edwards Lifesciences (NYSE:EW) chairman & CEO Michael Mussallem said the medical device company expects to post U.S. sales of $390 million-$440 million for its flagship Sapien heart valve, adding 200 new sites over the next 2 years to its existing roster of 200 sites.
- Show full page
- Login to post comments
-
Permalink
RECENT BLOG POSTS
- Rising healthcare costs not directly tied to medical technology, according to study
- CareFusion may be weighing 2 very different deals
- Medical Devices: What does it really mean to be disruptive?
- Smarter strategic moves bode well for Wright Medical
- The IRS, NSA, and Justice Department scandals and what they mean for HIPAA
- A Father's Day remembrance
- What I'd tell the graduating medical school class of 2013
- Silencing immune attacks in type 1 diabetes
- Eucomed guidance clarifies RoHS compliance for medical device companies
- How to simplify consents
Navigation
NEWS
J&J's Synthes unit wins $16M ruling in patent fight with Globus Medical
A Delaware jury sides with Johnson & Johnson's DePuy-Synthes subsidiary in a patent spat over 3...
Aneurysm: Covidien touts pivotal study on Pipeline embolization device
Results of pivotal study on Covidien subsidiary eV3's Pipeline cerebral aneurysm device, published in...
ForSight Vision5 gets new CEO, closes $9.3M funding round
Delphi Ventures' John Maroney joins ForSight Vision5 as president, CEO & Director as the...
Diabetes: Echo Therapeutics sends pre-submission package to FDA for Symphony needle-free CGM
Echo Therapeutics initiates discussions with the FDA on the regulatory pathway for its Symphony non-...
Real-world results cast doubt on renal denervation for high blood pressure
Study results revealed in Europe this week cast doubt on the efficacy of renal denervation for...
